<DOC>
	<DOCNO>NCT00111007</DOCNO>
	<brief_summary>The objective study compare anti-tumor activity measure Progression Free Survival ( PFS ) tolerability Sorafenib combination Paclitaxel Carboplatin versus Paclitaxel Carboplatin combination placebo subject unresectable Stage III Stage IV melanoma progress receive one prior therapy contain Dacarbazine ( DTIC ) Temozolomide ( TMZ ) .</brief_summary>
	<brief_title>A Treatment Combination Patients With Unresectable Stage III Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects life expectancy least 12 week Subjects histologically cytologically confirm unresectable ( Stage III ) metastatic ( Stage IV ) melanoma Subjects must progress receive least one cycle DTIC TMZ contain regimen Subjects ECOG PS 0 1 Measurable disease define least one lesion accurately serially measure per modify RECIST criterion Primary ocular mucosal melanoma Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta [ Noninvasive papillary carcinoma ] , Tis [ Carcinoma situ : `` flat tumor '' ] &amp; T1 [ Tumor invade subepithelial connective tissue ] ) cancer curatively treat &lt; 5 year prior study entry History cardiac disease Known history human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>